Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.
Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.
复制标题
DOI：
10.1016/j.tube.2017.11.009
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Hatherill M
中科院分区：
文献类型：
--
作者：
Fiore-Gartland A;Carpp LN;Naidoo K;Thompson E;Zak DE;Self S;Churchyard G;Walzl G;Penn-Nicholson A;Scriba TJ;Hatherill M
目前结核分枝杆菌（MTB）感染的诊断测试具有低预后特异性，用于识别将发展为结核病（TB）的个体，使得针对所有MTB感染个体的大规模预防性治疗策略在高负担TB国家不切实际。在这里，我们讨论了基于高度特异性转录组生物标志物的针对风险的检测和治疗策略的一般考虑因素，该生物标志物可以识别最有可能进展为活动性结核病的个体以及尚未就诊的结核病患者。医疗护理。这种针对风险的战略可以为减少结核病负担和阻断传播提供一条快速、合乎道德和具有成本效益的途径，对于在接近消除结核病的国家实现消除结核病也至关重要。我们还讨论了相关的风险有针对性的干预研究（CORTIS）的设计考虑，它可以提供的策略的概念验证。南非的一项此类研究目前正在招募1500名高风险和1700名低风险个体，根据生物标志物状态的定义，并将高风险参与者随机分配到结核病预防治疗或标准护理治疗。监测所有参与者进展为活动性TB，主要目的是评估治疗的功效和生物标志物的性能。
Current diagnostic tests for Mycobacterium tuberculosis (MTB) infection have low prognostic specificity for identifying individuals who will develop tuberculosis (TB) disease, making mass preventive therapy strategies targeting all MTB-infected individuals impractical in high-burden TB countries. Here we discuss general considerations for a risk-targeted test-and-treat strategy based on a highly specific transcriptomic biomarker that can identify individuals who are most likely to progress to active TB disease as well as individuals with TB disease who have not yet presented for medical care. Such risk-targeted strategies may offer a rapid, ethical and cost-effective path towards decreasing the burden of TB disease and interrupting transmission and would also be critical to achieving TB elimination in countries nearing elimination. We also discuss design considerations for a Correlate of Risk Targeted Intervention Study (CORTIS), which could provide proof-of-concept for the strategy. One such study in South Africa is currently enrolling 1500 high-risk and 1700 low-risk individuals, as defined by biomarker status, and is randomizing high-risk participants to TB preventive therapy or standard of care treatment. All participants are monitored for progression to active TB with primary objectives to assess efficacy of the treatment and performance of the biomarker.
登录
查看更多内容
DOI：
10.1183/13993003.01012-2016
发表时间：
2016-12
期刊：
The European respiratory journal
影响因子：
--
作者：
Petruccioli E;Scriba TJ;Petrone L;Hatherill M;Cirillo DM;Joosten SA;Ottenhoff TH;Denkinger CM;Goletti D
通讯作者：
Goletti D
表皮生长因子受体和KRAS突变对以前未经治疗的非小细胞肺癌患者的临床结果的影响：临床试验的在线肿瘤注册表的结果。
DOI：
10.1158/1078-0432.ccr-09-0888
发表时间：
2009-08-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Jackman DM;Miller VA;Cioffredi LA;Yeap BY;Jänne PA;Riely GJ;Ruiz MG;Giaccone G;Sequist LV;Johnson BE
通讯作者：
Johnson BE
影响因子：
8.7
作者：
Cliff JM;Kaufmann SH;McShane H;van Helden P;O'Garra A
通讯作者：
O'Garra A
影响因子：
82.9
作者：
Malherbe, Stephanus T.;Shenai, Shubhada;Walzl, Gerhard
通讯作者：
Walzl, Gerhard
影响因子：
3.7
作者：
Mahomed, Hassan;Ehrlich, Rodney;Hussey, Gregory Dudley
通讯作者：
Hussey, Gregory Dudley